Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals announced its participation in the 2026 European Academy of Dermatology and Venereology (EADV) Annual Meeting, presenting three abstracts related to imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP). The presentations highlight imsidolimab's efficacy in reducing neutrophils and improving GPP pustulation, as well as its immunogenicity profile. Imsidolimab is a fully humanized IgG4 monoclonal antibody inhibiting IL-36 receptor signaling, developed for the rare orphan indication of GPP, with regulatory and patent exclusivity expected until the late 2030s.
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). The study met its primary endpoint, showing a significant shift in sleep onset timing. Vanda plans to discuss these data with the FDA and submit a supplemental New Drug Application, aiming for HETLIOZ® to be the first FDA-approved medicine for DSWPD.
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda Pharmaceuticals (NASDAQ: VNDA) announced positive topline results from a pivotal Phase 3 trial for HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). The company plans to submit a supplemental New Drug Application to the FDA, which, if approved, would make HETLIOZ the first FDA-cleared medication for this specific circadian rhythm condition. The trial met its primary endpoint, demonstrating that HETLIOZ significantly advanced sleep onset compared to placebo.
Vanda Pharmaceuticals (VNDA) Reports Positive Phase III Results for HETLIOZ in DSWPD
Vanda Pharmaceuticals announced positive Phase III results for HETLIOZ in treating Delayed Sleep-Wake Phase Disorder (DSWPD), with plans for FDA submission. Despite this clinical success, the company faces financial challenges, including unprofitability and negative cash flow, reflected in its low Price-to-Sales ratio. Insider selling and mixed guru sentiment suggest caution, although the stock is deemed modestly undervalued by GuruFocus's GF Value™ metric.
Vanda Pharmaceuticals says Phase III HETLIOZ study met sleep endpoint
Vanda Pharmaceuticals announced positive Phase III results for HETLIOZ, with the study meeting its primary endpoint for treating delayed sleep-wake phase disorder in adults. Participants using tasimelteon achieved a 37.1-minute placebo-adjusted advance in sleep onset. Vanda plans to seek a third U.S. indication for HETLIOZ through a supplemental application, aiming to make it the first approved treatment for DSWPD.
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals announced positive Phase III results for HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). The study met its primary endpoint, showing a 37.1-minute earlier shift in sleep onset compared to placebo. Vanda plans to discuss these data with the FDA and submit a supplemental New Drug Application, aiming for HETLIOZ® to be the first FDA-approved medicine for DSWPD.
Vanda Pharmaceuticals' HETLIOZ® Study Achieves Positive Results
Vanda Pharmaceuticals announced positive Phase III results for its drug HETLIOZ® in treating Delayed Sleep-Wake Phase Disorder (DSWPD), showing a significant 37.1-minute earlier sleep onset for patients compared to placebo. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA, which, if approved, would make HETLIOZ® the first approved treatment for DSWPD, expanding Vanda's market presence and addressing an unmet medical need. This clinical success could bolster investor confidence despite recent stock fluctuations and sales declines for HETLIOZ®.
Vanda's Year-End Catalysts: Three Phase 3 Readouts And An FDA Decision Ahead
Vanda Pharmaceuticals Inc. is approaching a significant year-end with three Phase 3 clinical trial readouts and a crucial FDA regulatory decision. These upcoming catalysts, including the launch of BYSANTI and the PDUFA date for Quimilza, are expected to heavily influence the company's future pipeline and prospects. The article indicates these events are important milestones for biotech investors.
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com
Oppenheimer has initiated coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with an Outperform rating and a price target of $10.00, citing its transition into a diversified specialty pharmaceutical platform. The firm believes the market undervalues Vanda's pipeline, including drugs like Fanapt and Bysanti, and its potential new growth drivers, Nereus and Quimilza. Despite recent financial setbacks, Oppenheimer expects improved operating leverage and revenue acceleration, forecasting a return to profitability this year.
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced its participation in several investor conferences during September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference, with corporate presentations scheduled for some events. Live webcasts of certain presentations will be available on Vanda's corporate website.
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug
Vanda Pharmaceuticals, headquartered in Washington, D.C., has received Orphan Designation from the European Commission for its drug imsidolimab, intended to treat Generalized Pustular Psoriasis (GPP). This marks the first time a GPP treatment has received orphan status in the EU, following similar designations from the FDA and Japan. This designation provides Vanda with regulatory benefits and market exclusivity for imsidolimab, which is currently under FDA review with a target action date of December 12, 2026.
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced its participation in four investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the 2026 Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. Investors can access live corporate presentations from the Cantor and H.C. Wainwright conferences via Vanda's corporate website.
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live.
Vanda Pharmaceuticals (VNDA) announced its participation in four investor conferences in September 2026: Wells Fargo, Cantor, H.C. Wainwright, and Morgan Stanley. Corporate presentations at the Cantor and H.C. Wainwright conferences will be webcast live and archived on Vanda's website for approximately 30 days. This provides investors with opportunities to engage with the company and access presentation content.
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Vanda Pharmaceuticals announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher for Rahal Letterman Lanigan Racing, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. This historic NTT INDYCAR SERIES race on the National Mall celebrates America's 250th anniversary. NEREUS™ (tradipitant) is the first new U.S. prescription medication approved for the prevention of motion-induced vomiting in 47 years.
Vanda receives EU orphan designation for imsidolimab GPP treatment
Vanda Pharmaceuticals has received European Commission orphan designation for its drug imsidolimab for the treatment of generalized pustular psoriasis (GPP). This designation, the first for a GPP treatment in the EU, offers benefits like regulatory assistance and market exclusivity. Imsidolimab is also under FDA review in the U.S. with a target action date of December 12, 2026.
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Vanda Pharmaceuticals announced that its drug imsidolimab received Orphan Designation from the European Commission for Generalized Pustular Psoriasis (GPP), a severe inflammatory skin disease. This marks the first such recognition for a GPP treatment in the EU, following similar designations in the US and Japan. The drug, which inhibits IL-36 receptor signaling, is also under FDA review with a target action date of December 12, 2026.
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Vanda Pharmaceuticals announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis (GPP). This designation follows similar regulatory recognitions in the United States and Japan, and the imsidolimab Biologics License Application (BLA) for GPP is currently under review by the FDA with a target action date of December 12, 2026. GPP is a severe, chronic, and potentially life-threatening inflammatory skin disease, and imsidolimab works by inhibiting IL-36 receptor signaling.
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Vanda Pharmaceuticals Inc. announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. The race, held on the National Mall, celebrates America's 250th anniversary. NEREUS™ (tradipitant) is an FDA-approved medication for motion-induced vomiting, and this sponsorship highlights the brand's focus on performance.
VNDA: Psychiatry Franchise And Pipeline Catalysts Will Drive Future Earnings Repricing
Vanda Pharmaceuticals' fair value has been reduced from $14.90 to $12.19, reflecting a modest downgrade in its intrinsic value estimate. Analysts trimmed their price target from $17 to $12 due to a Q2 revenue miss, updated revenue growth expectations, and revised profit margins. The company reiterated its full-year 2026 revenue guidance between US$240 million and US$290 million and received Rare Pediatric Disease Designation for its investigational therapy VCA-894A.
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective passive stake of 3,376,401 shares in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), representing 5.6% of the outstanding common stock. They hold shared voting and dispositive power over these shares, indicating a joint investment approach rather than sole control. The filing clarifies that while the entities are subject to their voting control and investment discretion, this should not be construed as an admission of beneficial ownership for legal and reporting purposes.
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA
AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus rating and a $13.70 average price target. Despite this, the company recently missed analyst estimates for both earnings per share and revenue in its latest quarterly report.
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA
Monaco Asset Management SAM has acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), purchasing 221,286 shares valued at approximately $1.35 million. This investment makes Vanda Pharmaceuticals 0.1% of Monaco Asset Management SAM's portfolio and represents about 0.37% ownership of the company. The biopharmaceutical company recently reported weaker-than-expected quarterly earnings, missing analyst estimates for both EPS and revenue.
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044
Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts expected by year-end 2026, including for NEREUS, VQW-765, and HETLIOZ. Vanda anticipates its current resources and product revenue will fund operations through at least the end of 2027, with operating expenses expected to decline starting in late 2026.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages
Vanda Pharmaceuticals (NASDAQ:VNDA) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $13.70 despite recent reductions from some analysts. The company reported a larger-than-expected quarterly loss and missed revenue estimates, leading analysts to anticipate unprofitability for the current fiscal year. Despite this, institutional ownership remains high, with major firms increasing their stakes, while the stock trades significantly below its 12-month high.
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a passive ownership stake of 5.82% in Vanda Pharmaceuticals Inc. (VNDA), amounting to 3,497,695 shares. The SEC filing, a Schedule 13G, indicates that these entities have shared voting power over 3,313,298 shares and shared dispositive power over all 3,497,695 shares. This disclosure highlights AQR's significant but passive investment in the pharmaceutical company.
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst
HC Wainwright has significantly cut its Q3 2026 EPS estimate for Vanda Pharmaceuticals (NASDAQ: VNDA) to a loss of $0.61, down from $0.36, and projects a full-year 2026 loss of $3.03 per share, indicating deeper expected losses. This follows Vanda's recent miss on quarterly expectations, reporting a $1.04-per-share loss against a $0.58 consensus and lower-than-expected revenue. Despite these lowered estimates, HC Wainwright maintained a "Buy" rating with a $20 target, while other analysts have a "Moderate Buy" consensus rating with a $13.70 target.
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating
B. Riley has adjusted its price target for Vanda Pharmaceuticals to $12 from $17, while reiterating a "Buy" rating for the company. This news comes amidst other recent updates for Vanda, including their Q2 2026 earnings call, revenue guidance reiteration, and reports of positive opinions and designations for their investigational therapies. The article also provides an overview of Vanda Pharmaceuticals' commercial portfolio and pipeline.
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA
Dimensional Fund Advisors LP reduced its stake in Vanda Pharmaceuticals (NASDAQ:VNDA) by 16.4% in the first quarter, selling 346,835 shares but still holding 1.77 million shares valued at $12.24 million. The biopharmaceutical company reported weaker-than-expected Q1 results, with an adjusted loss of $1.04 per share and revenue of $50.53 million, both missing analyst estimates. Despite these results and the stock opening near its 52-week low, analysts maintain a "Moderate Buy" rating with a consensus price target of $14.30.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price
Vanda Pharmaceuticals Inc. recently reported disappointing second-quarter results, with revenues falling 18% short of analyst estimates and statutory losses exceeding expectations. Following this, analysts have downgraded revenue forecasts, increased projected per-share losses, and cut the consensus price target by 12% to US$12.44, reflecting concerns about the company's future valuation despite expectations for faster revenue growth than the broader industry.
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline
Vanda Pharmaceuticals reported a wider second-quarter 2026 net loss of $62.5 million, up from $27.2 million a year prior, as operating expenses surged to $114.3 million. Revenue declined 4% to $50.5 million, primarily due to a 66% drop in Hetlioz sales, while Fanapt sales rose 23%. The company reiterated its full-year revenue guidance and anticipates moderating expenses and key product launches, including BYSANTI and a December FDA decision for Quimilza.
Vanda Pharmaceuticals Inc. (VNDA) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Vanda Pharmaceuticals Inc. (VNDA), including its current stock price, recent news, financial statistics, and historical data. It details the company's product portfolio and pipeline, financial performance metrics, analyst ratings, and comparisons with similar biotechnology companies. The stock closed at $5.12, showing a slight increase from its previous close, and has a market cap of $309.267M.
Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen
Vanda Pharmaceuticals reported a wider-than-expected loss and lower-than-forecast revenue for Q2 2026, driven by a sharp decline in HETLIOZ sales despite growth in Fanapt and PONVORY. The company missed analyst estimates with an adjusted loss of $1.04 per share on revenue of $50.5 million, but reiterated its full-year revenue guidance and pointed to several upcoming clinical and regulatory catalysts. Vanda also expects operating expenses to moderate in late 2026 and 2027 and believes it has sufficient cash to fund operations through at least the end of 2027.
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals announced its second quarter 2026 financial results, highlighting a 23% increase in Fanapt® net product sales to $36.0 million and forecasting full-year 2026 total revenue between $240-$290 million. The company reported a cash balance of $170.0 million, expected to fund operations through at least 2027, and provided updates on recent FDA approvals, ongoing regulatory reviews, and upcoming clinical trial results for several key products, including BYSANTI™ and Quimilza™. Despite significant investments in new product launches leading to a net loss of $62.5 million for the quarter, Vanda anticipates operating expenses to moderate later in 2026 and more substantially in 2027.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) reported a Q2 loss of $1.04 per share, significantly missing the Zacks Consensus Estimate of a $0.51 loss, and also lagged revenue estimates with $50.53 million against an expected $62.67 million. The company's shares have fallen almost 40% year-to-date, and its Zacks Rank of #3 (Hold) suggests it will perform in line with the market. Another industry peer, Prothena (PRTA), is expected to report its Q2 results soon.
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview
Vanda Pharmaceuticals Inc is projected to report a loss of 59 cents per share. This information is part of an earnings preview. The full article by Refinitiv is available on TradingView.
Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Vanda Pharmaceuticals (NASDAQ: VNDA) had 561 employees worldwide as of March 2026, marking a 107.9% growth since 2023. The company is actively hiring, with 218 active job postings in 2026, and its workforce is primarily concentrated in North America, with Engineering being the largest and fastest-growing functional group. The average salary at Vanda Pharmaceuticals is $128,702.
Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m.
Vanda Pharmaceuticals (Nasdaq: VNDA) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can access the call via phone or Vanda's website, with a replay available until August 12, 2026.
Vanda Pharma (VNDA.US) Stock Price, Quote & News
This article provides an overview of Vanda Pharmaceuticals Inc. (VNDA.US) stock information, including its current price ($5.050), daily performance, and trading metrics. It also presents analyst ratings with a price forecast of $14.13 and a "Buy" consensus, along with recent news updates pertaining to the company's financial results, sponsorships, and FDA designations.
Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence
Vanda Pharmaceuticals Inc (VNDA) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 1.13% quarter-over-quarter to 78.40%, with James Simons being the largest institutional shareholder holding 6.25% of outstanding shares. Major institutional holders include BlackRock Institutional Trust Company, Renaissance Technologies LLC, and State Street Investment Management (US).
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Vanda Pharmaceuticals Inc (VNDA), highlighting its business segments and regional contributions. The data, updated on April 6, shows that the company's revenue is primarily driven by products such as Fanapt, Hetlioz, and PONVORY, with all revenue currently originating from the United States. It includes financial figures for fiscal years up to 2025.
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100
This article provides a comprehensive stock analysis of Vanda Pharmaceuticals Inc (VNDA) using TradingKey's stock score. It highlights the company's stable fundamentals, high growth potential, and fair valuation which ranks 78th in the Biotechnology & Medical Research industry. Despite recent weak stock market performance, VNDA shows strong fundamentals and is seen as suitable for range-bound swing trading with multiple analysts rating it as a "Buy" and a target price of 14.12.
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis
Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, positioning it 208th out of 386 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.32, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $17
B. Riley Securities has reiterated its Buy rating for Vanda Pharmaceuticals (VNDA.US), maintaining its target price at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks
This article lists various ETFs that hold Vanda Pharmaceuticals Inc. (VNDA) stocks, providing detailed financial information for each fund. The data includes market value, weight of VNDA in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), current price, daily percentage change, relative volume, and 3-year NAV total return. The information helps investors identify diversified opportunities to invest in Vanda Pharmaceuticals with potentially lower risk.
Vanda Pharmaceuticals - Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold
Vanda Pharmaceuticals is being downgraded to "Hold" due to increasing financial losses, significant cash burn, and uncertainties surrounding its pipeline execution. While Fanapt revenues are growing, the impending patent expiry and decline in Hetlioz sales pose a threat to near-term revenue stability. Although Bysanti and Nereus offer potential upside, their commercial viability and clinical milestones are unproven and have faced delays, with the company's cash potentially depleted by the end of 2027.
Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion for Orphan Drug Designation of Imsidolimab. This designation is for the treatment of Generalized Pustular Psoriasis (GPP). This news was reported by Reuters.
EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for its investigational product, imsidolimab, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA has recognized a GPP treatment with orphan drug designation in the EU, offering benefits like protocol assistance and market exclusivity. This follows similar regulatory recognitions in the US and Japan, and imsidolimab is currently under FDA review with a target action date of December 12, 2026.
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for imsidolimab, their investigational treatment for generalized pustular psoriasis (GPP). This marks the first time a drug for GPP has received such recognition in the EU, highlighting GPP as a distinct rare disease. The designation reinforces imsidolimab's clinical data and addresses an urgent unmet medical need, with the drug also under FDA review in the US.
Vanda Pharmaceuticals to be Primary Sponsor of Mick Schumacher’s INDYCAR Entry for Four Races Beginning in Nashville This Weekend
Vanda Pharmaceuticals will sponsor Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026, featuring their product NEREUS™ for motion sickness prevention. This marks Vanda's first venture into motorsports, adding to their high-profile sports sponsorships. Schumacher, son of Michael Schumacher, is in his first IndyCar season and has shown promise despite being new to the discipline.
Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value
Insiders of Vanda Pharmaceuticals Inc. sold US$2.8 million worth of stock over the last year at an average price of US$8.20, which is lower than the current share price but still higher than the latest price of US$5.85 after an 11% value drop. Despite the insider selling, the company's founder, Mihael Polymeropoulos, also made the biggest insider purchase of US$42k. Insiders collectively own 4.2% of the company, valued at US$15 million, indicating some alignment with shareholders.
